Efficacy and safety of therapy with biosimilar bevacizumab in the treatment of patients with metastatic colon cancer -a series of clinical observations
- 作者: Fedyanin M.Y.1, Elsnukaeva K.K.1, Pokataev I.A1, Sekhina O.V1, Chekini D.A1, Bulanov A.A1, Tryakin A.A1, Tyulyandin S.A1
-
隶属关系:
- N.N. Blokhin National Medical Research Center of Oncology
- 期: 编号 12 (2018)
- 页面: 55-59
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295811
- DOI: https://doi.org/10.18565/pharmateca.2018.12.55-59
- ID: 295811
如何引用文章
详细
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
Mikhail Fedyanin
N.N. Blokhin National Medical Research Center of Oncology
Email: fedianinmu@mail.ru
MD, Senior Researcher at the Department of Clinical Pharmacology and Chemotherapy
Kh. Elsnukaeva
N.N. Blokhin National Medical Research Center of Oncology
I. Pokataev
N.N. Blokhin National Medical Research Center of Oncology
O. Sekhina
N.N. Blokhin National Medical Research Center of Oncology
D. Chekini
N.N. Blokhin National Medical Research Center of Oncology
A. Bulanov
N.N. Blokhin National Medical Research Center of Oncology
A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology
S. Tyulyandin
N.N. Blokhin National Medical Research Center of Oncology
参考
- Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl J. Med. 2004;350(23):2335-42.
- Jang H.J., Kim B.J., Kim J.H., Kim H. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated metaanalysis of randomized trials. Oncotarget. 2017;8(42):73 009-16. Doi: 10.18632/ oncotarget.20314.
- Орлов С.В., Фогт С.Н., Шустовр М.С. Успешная регистрация отечественного биоаналога бевацизумаба - новые возможности эффективной терапии больных неплоскоклеточным немелкоклеточным раком легкого. Исследования и практика в медицине. 2015;2(4):132-36.
- Reinacher-Schick A.C., Arnold D., Dietrich G., et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol. 2008;26:A4030.
- Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-44
- Jain R.K. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science. 2005;307:58-62
- Aparicio T., Ghiringhelli F., Boige V., et al. Bevacizumab maintenance Versus No Maintenance During Chemotherapy-Free Intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018 Mar 1,36(7): 674-81. doi: 10.1200/JCO.2017.75.2931.
- Hurwitz H.I., Tebbutt N.C., Kabbinavar F., et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18(9):1004-12. Doi: 10.1634/ theoncologist.2013-0107.
- Venook A.P., Niedzwiecki D., Innocents F., et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34:3504.
- Hiret S., Christophe B., Bertaut A, et al. Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 - UNICANCER GI). J Clin Oncol. 2016,34:3514.
补充文件
![](/img/style/loading.gif)